Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond Authors: Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee Published: 2026 ABSTRACT AbstractIntroductionTwo‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.MethodsWe retrospectively identified virally suppressed PWH who switched from standard ART to DTG + 3TC at Queen Elizabeth Hospital, Hong Kong, China. They were grouped by age (PWH <50 years: PWH < 50; PWH > =50 years: PWH > =50). Their demographics, clinical and laboratory data before and 48 weeks after switch were compared.ResultsSubjects included 352 PWH (84.7% male, 48.7% PWH > =50, median ART duration 8.3 years). At 48 weeks post‐switch, 96.0% maintained DTG + 3TC with two (1.1%) in the PWH < 50 and three (1.7%) in the PWH > =50 experienced virological failure. There was no significant difference in virological failure (hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.11, 3.77, p = 0.613) or 2DR discontinuation (HR 0.95, 95% CI 0.33, 2.71, p = 0.926; restricted mean survival time (RMST) difference 0.23 weeks, 95% CI −0.64, 1.10, p = 0.600) between the groups. PWH > =50 exhibited a greater total cholesterol reduction than PWH < 50 post‐switch (median change −4.8% (IQR −17.5%, 5.9%) versus 0.4% (IQR −8.1%, 8.2%), p = 0.005). Two sensitivity analyses excluding lipid‐lowering drug users and restricting to INSTI‐based ART users before switch yielded negative results.ConclusionsIn this Chinese‐majority cohort, switching from standard ART to DTG + 3TC was well tolerated at 48 weeks by both younger and older PWH. Despite more comorbidities in PWH > =50, their changes in laboratory outcomes post‐switch were comparable to PWH < 50.Keywords: ageing, antiretroviral therapy, HIV, two‐drug regimen INTRODUCTION Traditionally, antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection has relied on three‐drug regimens to achieve durable virological suppression. Given that HIV infection cannot yet be cured, the challenges in long‐term toxicities and drug–drug interactions have prompted the exploration of ART simplification. Two‐drug regimens (2DRs) have emerged as a strategy to balance lifetime ART exposure while maintaining effective HIV control. Studies have demonstrated the safety and efficacy of 2DRs in virologically suppressed people with HIV (PWH) who have switched from conventional ART to second‐generation integrase strand transfer inhibitor (INSTI)‐based 2DRs. [1, 2, 3, 4, 5, 6] However, real‐world data on people of Asian descent and their longitudinal follow‐up of clinical and laboratory parameters remain insufficient. They often have a lower body mass index (BMI) than those of Caucasian descent, and older PWH may experience reduced metabolic rates compared to younger PWH. These differences highlight the need for further research to elucidate potential health disparities in these populations. The primary objective of this study was to examine the 48‐week virological outcomes in a group of virologically suppressed PWH who switched from conventional ART regimens to dolutegravir and lamivudine (DTG + 3TC) 2DR, which has been studied extensively [4, 5, 6, 7, 8]. The secondary objective was to study the longitudinal changes in clinical and laboratory parameters at 48 weeks post‐switch. For both objectives, we examined whether the observed changes differed between younger and older PWH (aged > = 50 years). We selected a 48‐week timeframe to align with regulatory and clinical standards for evaluating ART switch strategies, [9, 10, 11, 12] balancing feasibility and sample size while providing sufficient duration to capture early adverse events and tolerability issues. MATERIALS AND METHODS Study design This retrospective, longitudinal observational study was conducted at Queen Elizabeth Hospital (QEH), Hong Kong, China. QEH is a tertiary referral centre that has been serving PWH since 1985. We identified adult PWH (aged > = 18 years) who attended the HIV Clinic of QEH between 1 May 2014 and 30 April 2024 and switched from standard three‐drug ART to DTG + 3TC 2DR, which comprised the majority of DTG‐containing 2DRs being prescribed. Eligibility required pre‐switch virological suppression, continued adherence to DTG + 3TC and completion of 48 weeks of follow‐up. This ensured a consistent observation period and accurate assessment of treatment effects among those fully exposed to DTG + 3TC. PWH receiving concurrent entecavir with DTG + 3TC were excluded. Clinic attendees typically had visits and blood tests every three to six months, depending on clinical need. Blood tests were performed before follow‐up visits. Body mass index (BMI) was measured, and ART adherence was assessed using visual analogue scale (VAS) during follow‐up (Table S1). Clinical, laboratory and prescription data were retrieved from the Clinical Data Analysis and Reporting System (CDARS) and clinical records. CDARS is an electronic health record system administered by the Hospital Authority, a statutory public hospital service provider. [13] They included demographics (sex, ethnicity, age at 2DR switch), ART history (duration, pre‐switch and 2DR regimens), significant past medical history (smoking, chronic medical conditions including hypertension, diabetes mellitus (DM), hyperlipidaemia, cardiovascular disease (CVD), chronic kidney disease (CKD), non‐ART drug history), clinical parameters (body weight, BMI) and blood test results (CD4+ T‐lymphocyte count, CD4:CD8 T‐lymphocyte ratio, HIV viral load, urea, creatinine, estimated glomerular filtration rate (eGFR), calcium, phosphate, albumin, globulin, total bilirubin, alanine transaminase (ALT), alkaline phosphatase (ALP), fasting glucose, glycated haemoglobin (HbA1c), triglycerides, total cholesterol, high‐density lipoprotein (HDL) cholesterol and low‐density lipoprotein (LDL) cholesterol). Baseline characteristics were summarized in all subjects, followed by a subgroup comparison based on a cutoff age of 50 years at 2DR switch (i.e., PWH < 50 versus PWH > =50). This cut‐off to define older PWH has been widely adopted, [14, 15, 16] which captures the increased life expectancy with ART and the accelerated biological ageing seen in PWH, manifesting as earlier onset of age‐related comorbidities. Key clinical outcomes (virological response, 2DR discontinuation, all‐cause mortality) were described. Numerical values and percentage changes in the studied parameters (pre‐switch and 48 weeks post‐switch) were evaluated. Subgroup analyses comparing PWH < 50 with PWH >= 50 were performed. Due to blood collection timing variability, pre‐switch results were those closest to the switch date (±26 weeks), while 48‐week results were those nearest the 48‐week mark (48–74 weeks post‐switch). This approach balanced the need to reflect real‐world clinical practice with the unavoidable variability in sampling times. The study was approved by the Research Ethics Committee (Kowloon Central/Kowloon East) of the Hospital Authority (Ref: KC/KE‐23‐0195/ER‐4). Anonymized data were collected from records between 1 January 1995 and 31 March 2025. Definitions HIV virological response Virological suppression was defined as blood HIV RNA of <50 copies/mL. Viral blip was defined as a transient increase in HIV RNA levels of 50–200 copies/mL, immediately preceded and followed by virological suppression. Persistent low‐level viraemia was defined as any consecutive HIV RNA levels of 50–200 copies/mL. Virological failure was defined as any HIV RNA >200 copies/mL. Chronic medical conditions and medications Significant past medical conditions were retrieved, supplemented with individuals' laboratory results and prescription records. The definitions are detailed in the Table S1. CKD was defined as eGFR <60 mL/min/1.73 m2 in the closest two consecutive kidney function tests (> = 3 months apart), before the 2DR switch. [17] eGFR calculation was based on the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation. [18] For the use of lipid‐lowering drugs, 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors (statins) were further classified into low‐, moderate‐ and high‐intensity according to the drug substance and total daily dosage, as defined by the American College of Cardiology/American Heart Association classification [19]. Statistical analysis Parameters and outcomes were presented as number (percentage) and median (interquartile range, IQR) as appropriate. Cross‐sectional comparisons used chi‐square, Fisher's exact (small cell counts) or non‐parametric tests. Kaplan‐Meier curves for virological suppression and 2DR discontinuation were generated, with between‐group difference assessed using log‐rank tests. The proportional hazards assumption was verified using Schoenfeld residuals and complementary log‐log plots. When violated, the restricted mean survival time (RMST) difference up to 48 weeks post‐switch was used as the primary summary measure. RMST provides a more accurate comparison of the studied groups when the proportional hazards assumption is not met. Percentage change in the studied parameters was calculated as (post‐switch value − pre‐switch value) / pre‐switch value × 100. The Wilcoxon rank‐sum test was used to identify parameters with significant differences in median percentage changes between groups PWH < 50 and PWH > =50. For parameters showing statistical significance in univariate analysis, data were further analysed using a linear mixed‐effects model (LMM) to estimate the parameter trajectories over time with adjustment for varying follow‐up intervals. We fit the model treating the target parameter as the outcome variable, with time (in weeks between the dates of pre‐ and post‐switch tests) as a continuous fixed effect and additional fixed effects for selected covariates. A random intercept for each subject was included to account for within‐individual correlation. Percentage change was derived post‐hoc from the time slope, with 95% confidence intervals (CIs) and p‐values via parametric bootstrapping with 1000 simulations. Model assumptions were verified using diagnostic plots and tests: the Breusch‐Pagan test for heteroscedasticity, and DHARMa (Residual Diagnostics for HierARchical Models) simulated residuals (including Q‐Q plot for normality, Kolmogorov‐Smirnov (KS) test for uniformity and checks for dispersion and outlier). A two‐sided p‐value <0.05 was considered statistically significant. All analyses were conducted using R statistical software (version 4.5.2; R Core Team, 2025). RESULTS Baseline characteristics By 30 April 2024, 353 PWH met the selection criteria, with one of them excluded due to concomitant use of entecavir. The remaining 352 PWH (84.7% males, 86.4% ethnic Chinese) had a median of 8.3 years of ART experience at the time of DTG + 3TC switch. Before switching, most were receiving INSTI‐based ART (80.7%), followed by non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐based regimens (14.2%). Around 10% and 30% of pre‐switch ART contained tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), respectively. Compared to the PWH < 50 group, the PWH > =50 group had more frequent use of separate DTG and 3TC tablets (p = 0.001), longer ART experience, more frequent prior use of NNRTI‐based ART, hypoglycaemic drugs and lipid‐lowering drugs, and higher rates of hypertension, DM, hypoglycaemic drug use, CVD and CKD (all p < 0.001) (Table 1). Among individuals who used separate DTG and 3TC tablets, 54.2% of them had a pre‐switch eGFR <60 mL/min/1.73 m2. The PWH > =50 group had significantly lower pre‐switch body weight (but not BMI), CD4+ T‐lymphocyte count, eGFR, albumin and calcium levels than the PWH < 50 group (all p < 0.05). The PWH > =50 group also had significantly higher urea, globulin, ALP, fasting glucose, HbA1c and triglycerides (all p < 0.05) (Table 2). TABLE 1Baseline characteristics before DTG + 3TC switch.All PWH switched to DTG + 3TC (n = 352)PWH switched to DTG + 3TC with age < 50 years (PWH < 50) (n = 180)PWH switched to DTG + 3TC with age > =50 years (PWH > =50) (n = 172) p‐valueFemale (n, %)54 (15.3%)17 (9.4%)37 (21.5%)0.003 a Chinese ethnicity (n, %)304 (86.4%)154 (85.6%)150 (87.2%)0.767 a Age at 2DR switch (years)50 (37–58)38 (33–45)58 (54–60)<0.001 b ART experience (years)8.3 (4.1–9.9)5 (3.5–6.8)13.3 (8.1–13.1)<0.001 b Pre‐switch ART (n, %)INSTI backbone284 (80.7%)162 (90.0%)122 (70.9%)<0.001 a NNRTI backbone50 (14.2%)12 (6.7%)38 (22.1%)<0.001 a PI backbone18 (5.1%)6 (3.3%)12 (7.0%)0.217 a TDF‐containing36 (10.2%)20 (11.1%)16 (9.3%)0.701 a TAF‐containing105 (29.8%)62 (34.4%)43 (25.0%)0.069 a 2DR formulations (n, %)DTG + 3TC (separate tablets)24 (6.8%)4 (2.2%)20 (11.6%)0.001 a DTG + 3TC (co‐formulation)328 (93.2%)176 (97.8%)152 (88.4%)Ever smoker (n, %)155 (44.0%)82 (45.6%)73 (42.4%)0.631 a Active smoker (n, %)105 (29.8%)63 (35.0%)42 (24.4%)0.040 a Hypertension (n, %)110 (31.2%)24 (13.3%)86 (50.0%)<0.001 a Diabetes mellitus (n, %)55 (15.6%)13 (7.2%)42 (24.4%)<0.001 a Use of hypoglycaemic drug (n, %)26 (7.4%)3 (1.7%)23 (13.4%)<0.001 a Use of lipid‐lowering drug (n, %)83 (23.6%)14 (7.8%)69 (40.1%)<0.001 a All statins69 (19.6%)13 (7.2%)56 (32.6%)<0.001 a Low‐intensity statins5 (1.4%)1 (0.6%)4 (2.3%)0.206 c Moderate‐intensity statins53 (15.1%)12 (6.7%)41 (23.8%)<0.001 a High‐intensity statins11 (3.1%)0 (0%)11 (6.4%)NAEzetimibe2 (0.6%)0 (0%)2 (1.2%)NAGemfibrozil11 (3.1%)0 (0%)11 (6.4%)NAFenofibrate4 (1.1%)1 (0.6%)3 (1.7%)0.372 c Cardiovascular disease (n, %)28 (8.0%)3 (1.7%)25 (14.5%)<0.001 a Chronic kidney disease (n, %)18 (5.1%)0 (0%)18 (10.5%)<0.001 a Note: Median (IQR) unless otherwise specified.Abbreviations: ART, antiretroviral therapy; DTG, dolutegravir; INSTI, integrase strand transfer inhibitor; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; PWH, people with HIV; TAF, tenofovir alafenamide; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate. a By chi‐square test. b By Wilcoxon rank‐sum test. c By Fisher's exact test. Baseline characteristics before DTG + 3TC switch. Note: Median (IQR) unless otherwise specified. Abbreviations: ART, antiretroviral therapy; DTG, dolutegravir; INSTI, integrase strand transfer inhibitor; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; PWH, people with HIV; TAF, tenofovir alafenamide; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate. By chi‐square test. By Wilcoxon rank‐sum test. By Fisher's exact test. TABLE 2Clinical and laboratory parameters before and 48 weeks or more after the DTG + 3TC switch.Pre‐switchPost‐switchPWH < 50PWH > =50 p‐value a PWH < 50PWH > =50 p‐value a Body weight (kg)70.0 (63.3, 77.9)66.2 (56.3, 75.3)0.00870.5 (64.0–78.5)65.6 (57.5–76.4)0.001BMI (kg/m2)23.9 (22.0, 26.0)24.3 (21.6, 27.3)0.94424.2 (22.4–26.4)23.8 (21.4–26.7)0.364CD4+ T‐lymphocyte (cells×109/L)548.0 (426.0, 771.0)516.5 (394.5, 662.0)0.046568.5 (427.8–748.2)527.5 (381.2–670.0)0.066CD4:CD8 lymphocyte ratio0.7 (0.5, 0.9)0.8 (0.6, 1.1)0.2730.8 (0.6–1.0)0.8 (0.6–1.1)0.655Urea (mmol/L)4.9 (4.1, 6.0)5.4 (4.5, 6.7)0.0025.1 (4.3–6.0)5.5 (4.9–6.8)<0.001Creatinine (μmol/L)90.0 (81.0, 100.0)91.0 (76.2, 108.8)0.76890.0 (83.0–102.5)96.0 (79.0–112.0)0.135eGFR (mL/min/1.73 m2) b 93.0 (80.4, 101.7)78.2 (63.3, 89.3)<0.00189.2 (77.3–99.7)71.6 (61.2–82.6)<0.001Calcium (mmol/L)2.4 (2.3, 2.4)2.3 (2.3, 2.4)0.0252.3 (2.3–2.4)2.3 (2.3–2.4)0.430Phosphate (mmol/L)1.1 (1.0, 1.2)1.1 (1.0, 1.2)0.4211.2 (1.0–1.2)1.1 (1.0–1.2)0.027Albumin (g/L)40.3 (38.4, 42.0)38.9 (37.5, 40.8)<0.00140.1 (38.4–42.3)38.8 (37.2–40.3)<0.001Globulin (g/L)35.2 (33.3, 38.1)36.5 (34.5, 39.5)0.00234.6 (32.6–37.3)36.3 (34.4–38.5)0.001Total bilirubin (μmol/L)8.2 (6.0, 10.1)7.8 (6.1, 9.8)0.6448.6 (6.8–11.3)9.1 (7.2–11.8)0.226ALT (U/L)24.0 (18.0, 33.0)24.4 (19.0, 32.0)0.48323.0 (18.0–31.8)23.0 (18.0–30.0)0.974ALP (U/L)71.0 (61.0, 82.0)76.5 (63.0, 93.8)0.00366.5 (58.0–77.0)75.0 (61.0–88.0)0.002Fasting glucose (mmol/L)5.0 (4.7, 5.4)5.4 (5.0, 6.0)<0.0014.9 (4.7–5.4)5.5 (5.0–6.0)<0.001HbA1c (%)5.3 (5.1, 5.6)5.7 (5.4, 6.1)<0.0015.5 (5.3–5.9)6.2 (5.8–6.8)<0.001Triglycerides (mmol/L)1.2 (0.8, 1.8)1.5 (1.1, 2.2)<0.0011.1 (0.8–1.7)1.4 (1.0–2.1)0.018Total cholesterol (mmol/L)4.9 (4.3, 5.4)4.9 (4.3, 5.6)0.4074.9 (4.3–5.3)4.7 (3.8–5.4)0.058HDL cholesterol (mmol/L)1.3 (1.1, 1.5)1.3 (1.0, 1.5)0.7821.3 (1.1–1.5)1.2 (1.0–1.5)0.154LDL cholesterol (mmol/L)2.8 (2.2, 3.4)2.7 (2.2, 3.4)0.5082.9 (2.4–3.3)2.7 (2.0–3.3)0.008 Note: Median (IQR) unless otherwise specified.Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; DTG, dolutegravir; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PWH, people with HIV; 3TC, lamivudine. a By Wilcoxon signed rank test. b By the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation. Clinical and laboratory parameters before and 48 weeks or more after the DTG + 3TC switch. Note: Median (IQR) unless otherwise specified. Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; DTG, dolutegravir; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PWH, people with HIV; 3TC, lamivudine. By Wilcoxon signed rank test. By the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation. Three individuals in the PWH < 50 group and two in the PWH > =50 group were lost to follow‐up or transferred to other healthcare institutions, with a significant between‐group difference. Two individuals in the PWH > =50 group died from causes unrelated to HIV (Table 3). At 48 weeks post‐switch, 173 individuals from the PWH < 50 group and 165 from the PWH > =50 group remained on 2DR. Of these, 155 (PWH < 50) and 145 (PWH > =50) had > = 1 target parameter available for analysis. The flow of PWH studied is shown in Figure S1. TABLE 3Clinical events in the first 48 weeks after DTG + 3TC switch.PWH < 50 (n = 180)PWH > =50 (n = 172) p‐valueVriological outcomeVirological failure a 2 d (1.1%)3 (1.7%)0.679 e Persistent low‐level viraemia b 0 (0%)1 (0.6%)NAViral blip c 4 d (2.2%)2 (1.2%)0.685 e 2DR discontinuationAll‐cause7 (3.9%)7 (4.1%)1 f Due to virological failure1 (0.6%)1 (0.6%)1 e Due to side effects1 (0.6%)2 (1.2%)0.616 e Switched to LAI ART2 (1.1%)0 (0%)NADefaulted1 (0.6%)1 (0.6%)1 e Referred out to other institutions2 (1.1%)1 (0.6%)1 e Death (all‐cause)0 (0%)2 (1.2%)NAAbbreviations: ART, antiretroviral therapy; DTG, dolutegravir; 2DR: two‐drug regimen; LAI, long‐acting injectable; NA, not applicable; PWH, people with HIV; 3TC, lamivudine. a Virological failure was defined as any blood HIV RNA >200 copies/mL. b Persistent low‐level viraemia was defined as any consecutive blood HIV RNA levels of 50–200 copies/mL. c Viral blip was defined as a transient increase in blood HIV RNA levels of 50–200 copies/mL, immediately preceded and followed by virological suppression. d One PWH < 50 developed viral blip and then virological failure separated by a period of virological suppression. e By Fisher's exact test. f By chi‐square test. Clinical events in the first 48 weeks after DTG + 3TC switch. Abbreviations: ART, antiretroviral therapy; DTG, dolutegravir; 2DR: two‐drug regimen; LAI, long‐acting injectable; NA, not applicable; PWH, people with HIV; 3TC, lamivudine. Virological failure was defined as any blood HIV RNA >200 copies/mL. Persistent low‐level viraemia was defined as any consecutive blood HIV RNA levels of 50–200 copies/mL. Viral blip was defined as a transient increase in blood HIV RNA levels of 50–200 copies/mL, immediately preceded and followed by virological suppression. One PWH < 50 developed viral blip and then virological failure separated by a period of virological suppression. By Fisher's exact test. By chi‐square test. Clinical events in the first 48 weeks post‐switch Virological outcomes Five PWH experienced virological failure before reaching 48 weeks post‐switch, and three of them received genotypic resistance testing (GRT). All of them were on DTG + 3TC co‐formulation. The median time to failure was 20.0 weeks (IQR 14.4, 26.0). Two were in the PWH < 50 group while three were in the PWH > =50 group (1.1% versus 1.7%, p = 0.679). Both individuals in the PWH < 50 group developed virological failure 24–48 weeks post‐switch, while all three individuals in the PWH > =50 group experienced virological failure before week 24. By log‐rank test, there was no significant between‐group difference in virological failure development (p = 0.613) (Figure 1). The proportional hazards assumption was not violated, as confirmed by Schoenfeld residuals (p = 0.054) and a parallel complementary log‐log plot. Kaplan‐Meier survival curve of maintaining virological suppression within 48 weeks after switching from conventional ART to DTG + 3TC in groups PWH < 50 and PWH >= 50. Log‐rank test (p = 0.613). In the PWH < 50 group, the two individuals reported satisfactory adherence to their 2DR. One continued DTG + 3TC in view of failed GRT and achieved virological suppression. The other switched back to conventional ART followed by suppression, though GRT did not detect a major resistance mutation. Of the three individuals in the PWH > =50 group, the first admitted ART adherence issues, switched back to conventional ART and regained suppression, and GRT was negative for resistance mutation. The second individual also reported ART adherence issues but continued DTG + 3TC in the absence of GRT. Virological suppression was achieved subsequently. The third individual reported good ART adherence and continued DTG + 3TC without GRT. Virological suppression was later attained. One individual in the PWH > =50 group exhibited persistent low‐level viraemia, while four in the PWH < 50 group and two in the PWH >=50 group exhibited viral blips. Comparing the frequencies of virological failure, low‐level viraemia and viral blips between the two groups did not reveal any statistical difference (Table 3). 2DR discontinuation Including the two aforementioned individuals who switched back to conventional ART due to virological failure, seven individuals in the PWH < 50 group and seven in the PWH > =50 group discontinued DTG + 3TC within 48 weeks from switch (3.9% versus 4.9%, p = 1). One (0.6%) in the PWH < 50 group and two (1.2%) in the PWH > =50 group switched back to conventional ART due to side effects related to 2DR. Two (1.1%) in the PWH < 50 group switched to long‐acting injectable (LAI) ART. The details are summarized in Tables 3. Similarly, the log‐rank test produced no significant difference between the two groups (p = 0.926) (Figure 2). Because the survival curves and complementary log‐log plots crossed during follow‐up period, indicating non‐proportional hazards despite a non‐significant Schoenfeld residual test (p = 0.6), the RMST difference was therefore used as the primary summary measure. No statistically significant difference was observed between the two groups (RMST difference: 0.23 weeks, 95% CI −0.64, 1.10, p = 0.600). Kaplan‐Meier survival curve for continuation of DTG + 3TC within 48 weeks after switching from conventional ART in groups PWH < 50 and PWH > =50. Log‐rank test (p = 0.926). Crossing survival curves indicate non‐proportional hazards. The RMST difference was reported as the primary measure. Clinical and laboratory parameters The median percentage changes in target parameters pre‐ and post‐switch are summarized in Table 4. Taking all subjects into account, the level of total bilirubin exhibited a significant increase after switching to DTG + 3TC (pre‐switch median 7.9 μmol/L (IQR 6.1, 9.9) versus post‐switch median 8.7 μmol/L (IQR 7.0, 11.7), p < 0.001), resulting in a 13.4% increase (IQR −10.0%, 50.0%). The level of triglycerides trended towards a significant decrease post‐switch (pre‐switch median 1.4 mmol/L (IQR 0.9, 2.1) versus post‐switch median 1.3 mmol/L (IQR 0.9, 2.0), p = 0.07), resulting in 11.5% decrease (IQR −31.0%, 14.7%). TABLE 4Percentage change in clinical and laboratory parameters.Percentage change in parameter values from baseline (measured from 26 weeks pre‐switch to switch) to 48 weeks post‐switch (measured 48–74 weeks post‐switch) p‐value a All subjectsPWH < 50PWH > =50Percentage changePercentage changePercentage changeBody weight (kg)2.6% (−0.5%, 4.9%)2.9% (−0.2%, 5.3%)2.4% (−0.6%, 4.4%)0.449BMI (kg/m2)2.6% (−0.5%, 4.8%)2.9% (0.0%, 5.2%)2.4% (−0.5%, 4.4%)0.470CD4+ T‐lymphocyte (cells×109/L)−0.6% (−12.5%, 12.0%)−0.3% (−13.8%, 14.3%)−1.2% (−12.1%, 10.7%)0.675CD4:CD8 lymphocyte ratio5.5% (−4.8%, 20.0%)5.9% (−4.7%, 20.7%)5.3% (−5.6%, 17.6%)0.480Urea (mmol/L)2.3% (−12.3%, 20.5%)3.5% (−13.1%, 21.9%)1.6% (−11.6%, 18.3%)0.930Creatinine (μmol/L)2.3% (−4.1%, 10.3%)2.1% (−3.4%, 9.2%)2.5% (−4.3%, 11.5%)0.391eGFR (mL/min/1.73 m2)−3.0% (−10.3%, 3.4%)−3.0% (−10.3%, 2.7%)−2.9% (−10.2%, 4.4%)0.793Calcium (mmol/L)0.0% (−2.3%, 2.0%)−0.3% (−3.0%, 1.6%)0.4% (−1.7%, 2.4%)0.075Phosphate (mmol/L)4.4% (−6.6%, 17.1%)6.1% (−6.3%, 18.3%)2.5% (−6.6%, 15.3%)0.270Albumin (g/L)−0.8% (−4.4%, 2.8%)−0.3% (−4.4%, 3.0%)−1.7% (−4.4%, 2.5%)0.154Globulin (g/L)−2.0% (−6.9%, 3.3%)−2.2% (−6.7%, 3.5%)−1.7% (−7.1%, 3.2%)0.980Total bilirubin (μmol/L)13.4% (−10.0%, 50.0%)11.9% (−13.5%, 53.5%)14.5% (−6.0%, 46.2%)0.353ALT (U/L)−3.3% (−23.1%, 26.7%)−0.9% (−22.5%, 28.4%)−3.4% (−23.1%, 25.0%)0.438ALP (U/L)−4.6% (−14.1%, 4.4%)−3.9% (−13.1%, 7.7%)−5.2% (−14.9%, 3.2%)0.497Fasting glucose (mmol/L)−0.4% (−5.2%, 4.8%)−0.7% (−4.6%, 4.3%)−0.2% (−5.4%, 5.4%)0.919HbA1c (%)3.8% (0.0%, 8.7%)3.8% (0.0%, 7.3%)5.1% (0.0%, 9.1%)0.739Triglycerides (mmol/L)−11.5% (−31.0%, 14.7%)−5.4% (−30.0%, 22.7%)−15.0% (−31.8%, 4.0%)0.123Total cholesterol (mmol/L)−2.1% (−11.7%, 7.7%)0.4% (−8.1%, 8.2%)−4.8% (−17.5%, 5.9%)0.005HDL cholesterol (mmol/L)−1.0% (−10.1%, 9.2%)−0.9% (−8.0%, 8.6%)−1.2% (−11.1%, 9.3%)0.554LDL cholesterol (mmol/L)0.0% (−13.9%, 15.4%)1.0% (−11.3%, 14.1%)−3.0% (−20.3%, 15.7%)0.080 Note: Median (IQR) unless otherwise specified. Only PWH with completed pairs of pre‐switch and post‐switch measurement were included.Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PWH, people with HIV. a By Wilcoxon rank‐sum test. Percentage change in clinical and laboratory parameters. Note: Median (IQR) unless otherwise specified. Only PWH with completed pairs of pre‐switch and post‐switch measurement were included. Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PWH, people with HIV. By Wilcoxon rank‐sum test. Comparing the PWH < 50 and PWH >= 50 groups, there was no significant difference in median percentage change for all clinical and laboratory parameters, except a greater reduction in total cholesterol in the PWH >= 50 group (0.4% (IQR −8.1%, 8.2%) versus −4.8% (IQR −17.5%, 5.9%), p = 0.005). Between their 2DR switch dates and blood tests closest to 48 weeks post‐switch, nine individuals in the PWH < 50 group and 19 individuals in the PWH > =50 group initiated lipid‐lowering drugs. All 19 individuals in the PWH > =50 group started moderate‐intensity statins at a median time of 30.1 weeks (IQR 25.4, 45.2) after switch. In the PWH < 50 group, seven individuals began low‐intensity statins, one initiated moderate‐intensity statins and one received gemfibrozil, with a median time of 33.0 weeks (IQR 25.1, 43.0) post‐switch. A sensitivity analysis was performed by excluding 114 individuals (23 and 91 in the PWH < 50 and PWH > =50 groups respectively) who either took lipid‐lowering drugs before the switch and initiated lipid‐lowering drugs between switch dates and their blood tests later and closest to the 48‐week mark. Percentage change in the total cholesterol did not differ significantly between the PWH < 50 and PWH > =50 groups (p = 0.253). A second sensitivity analysis was performed by only selecting those who switched from INSTI‐based ART to DTG + 3TC. This excluded individuals using ART regimens with either NNRTI or PI backbones, which have been shown to impact cholesterol levels. [20, 21, 22, 23] Similarly, it did not show a significant difference in the percentage change of total cholesterol between the two groups (p = 0.329). Total cholesterol change was additionally evaluated using a LMM adjusted with age (as PWH < 50 and PWH > =50 categories), sex, ethnicity, hypertension, DM, use of lipid‐lowering drugs (from one year prior to up to 48 weeks post‐switch), statin intensity, use of ezetimibe, CVD, CKD, baseline CD4+ T‐lymphocyte count and time (in weeks between the dates of pre‐ and post‐switch cholesterol tests). The LMM showed a significant decline in predicted cholesterol over time, with an estimated slope of −0.003 mmol/L per week (95% CI −0.005, −0.001, p < 0.001). Adjusted average percentage change at 48 weeks was −3.147% (95% CI −5.097, −1.216, bootstrapped p = 0.002). These values corresponded to an absolute reduction of 0.14 mmol/L from a median pre‐switch total cholesterol baseline of 4.9 mmol/L in both PWH < 50 and PWH > =50 groups. Significant covariates included hypertension (p = 0.044) and presence of CVD (p = 0.025). Breusch‐Pagan test suggested no strong evidence of heteroscedasticity (p = 0.09). DHARMa diagnostics supported assumptions (Q‐Q plot points followed the diagonal line, KS test (p = 0.12), dispersion (p = 0.55), outliers (p = 0.81)) with minor quartile deviations. DISCUSSION DTG‐containing regimens have demonstrated a favourable safety and efficacy profile in clinical trials. Nevertheless, real‐world performance can differ, and data from specific populations remain limited. To address these gaps, this study examined the 48‐week virological, clinical and laboratory outcomes of virally suppressed PWH who switched to a 2DR consisting of DTG and 3TC, a regimen that is available across regions of different economic statuses. Over 85% of the included individuals were Chinese and nearly half were > =50 years at the time of the switch. Baseline differences between age groups at the switch are expected in older PWH and are transparently reported. In line with the efficacy, tolerance and safety profile of DTG + 3TC in published trials, [5, 24, 25, 26] our findings indicated that 96% of PWH maintained the treatment at week 48. Additionally, younger and older PWH did not show differences in virological outcomes, nor did they exhibit different rates of DTG + 3TC discontinuation. In this study, virological failure was defined as a single HIV RNA >200 copies/mL, rather than the more common criterion requiring confirmed elevations. Despite using a stricter definition, no statistically significant difference was observed between the PWH < 50 and PWH > =50 groups, suggesting that commonly used definitions yield comparable results. Although the low event rate (1.4%, 5/352) limited between‐group comparisons, it aligns with real‐world meta‐analyses. [27, 28] The overall DTG + 3TC discontinuation rate at week 48 was 4.0% (14/352), with no significant difference between the PWH < 50 and PWH > =50 groups. This rate was comparable to the 3.5% reported for the DTG + 3TC group in the TANGO study at week 48. [4] In the OPERA cohort, discontinuation rates were similar between those aged <50 years (21.2%, 104/490) and > =50 years (22.2%, 66/297) [29]. An increase in post‐switch total bilirubin levels compared to its pre‐switch levels was observed among all PWH. DTG is metabolized by the hepatic enzyme uridine diphosphate glucuronosyltransferase (UGT1A1). [30, 31] UGT1AI polymorphism has been reported in Asians. [32, 33] In the SPRING‐2 study, a statistically significant association between DTG exposure and increased total bilirubin was attributed to the competition of DTG and unconjugated bilirubin to UGT1A1. [34] Besides, DTG has been shown to displace albumin from bilirubin, causing increased free bilirubin concentration in vitro [35]. The PWH > =50 group exhibited a greater percentage reduction in total cholesterol compared with the PWH < 50 group, and LMM analysis suggested a significant decline in predicted cholesterol over time in all PWH. However, the modest 3% reduction observed over 48 weeks may not be clinically meaningful, considering its small magnitude (−0.003 mmol/L per week) and negligible anticipated real‐world effects. Also, the two sensitivity analyses showed negative results. The absence of significant changes in LDL cholesterol further limits the practical relevance of these findings. TAF is associated with greater weight gain and increases in cholesterol, LDL and triglycerides compared to TDF, which tends to lower lipids and promote modest weight loss. [36, 37] In the current study, there was no significant difference in the proportion of pre‐switch TDF and TAF usage between the PWH < 50 and PWH > =50 groups. The small number of subjects (n < 30) who had taken pre‐switch TDF and had complete pre‐ and post‐switch cholesterol data precluded further analysis. However, no significant differences were observed in the percentage changes of cholesterol (p = 0.124) or LDL (p = 0.471) between pre‐switch TAF users (n = 86) and individuals who had not used TDF or TAF (n = 168). Future studies with larger sample sizes are warranted to clarify the clinical relevance of these findings. This study has limitations. First, as a retrospective observational study lacking a three‐drug ART control arm, we cannot definitively attribute metabolic changes (e.g. weight, lipids) solely to the DTG + 3TC switch, as ageing, lifestyle or other factors may contribute. Baseline differences in older PWH, such as longer ART exposure and more comorbidities, may contribute to confounding by indication. In real‐world practice, switches were clinician‐ and individual‐driven considering pill burden, drug interactions and preferences. Our findings align with real‐world cohorts [29, 38, 39] and randomized control trials (e.g. TANGO [4], SALSA [6]), supporting DTG + 3TC tolerability. Second, unlike prospective studies with better scheduling, this study retrospectively collected outcomes closest to the dates of 2DR switch and the 48‐week mark. Many outcome parameters were not measured on the same day. The sampling windows were pragmatically defined as <=26 weeks pre‐switch and 48–74 weeks post‐switch to reflect routine clinical practice. While this may introduce temporal variability in metabolic parameters across participants, a sampling period exceeding 48 weeks is generally considered sufficient to detect significant longitudinal changes in laboratory parameters from a safety perspective. Yet regression adjustments for the time between pre‐ and post‐switch assessments ensured comparable 2DR exposure, supporting the robustness of our findings. Third, the study only captured the parameters collected closest to the date of week 48 post‐switch, potentially missing important changes between the checkpoints. Fourth, the clinical parameter analysis excluded subjects who did not complete 48 weeks of DTG + 3TC, raising the possibility of survivor bias. However, the number excluded was small (14/352, <4% of the sample size), and most discontinuations (9/14) were for reasons unrelated to the 2DR regimen (e.g. loss to follow‐up, switch to long‐acting injectable ART or death). One of the two individuals with virological failure reported suboptimal ART adherence. These suggest minimal impact of survivor bias. Also, the aim of comparing clinical parameters was to identify those with significant changes in PWH who tolerated DTG + 3TC well. Next, long‐term (>48 weeks) outcomes were not deeply analysed. Additionally, the retrospective design limited assessment of other post‐DTG outcomes, including appetite, sleep quality and mood. [40, 41] The unavailability of cystatin C measurement and missing albuminuria/proteinuria data further restricted interpretation of renal outcomes. Finally, ART adherence was recorded by VAS and was not included in the regression model, as sustained virological suppression at baseline and throughout follow‐up already served as a reliable objective surrogate marker for adequate adherence. CONCLUSIONS This study examines the virological outcome, tolerance and longitudinal changes in selected clinical and laboratory parameters among younger and older PWH who switched from standard ART to DTG + 3TC. Despite the inherent limitations of our observational data, such as unmeasured confounders that warrant cautious interpretation, the results demonstrated favourable tolerance and safety profiles in both young and older PWH, with both groups showing comparable changes in tested parameters. These findings indicate acceptable long‐term safety and tolerability of DTG + 3TC across age groups in real‐world Asian cohorts, highlighting its potential as a simplified and durable ART option. AUTHOR CONTRIBUTIONS Conceptualization: THCT, PC, RTSK, MPL. Study design: THCT, PC, RTSK, MPL. Data acquisition: THCT, RTSK, KWL, DKYY. Data analysis: THCT. Patient care: THCT, RTSK, KWL, HSYC, MYC, WL, TCW, WSL, SKY, WMT, AKTC, JLFT, JKWF, MPL. Manuscript preparation: THCT, PC, RTSK, KWL, HSYC, MYC, WL, TCW, WSL, SKY, WMT, AKTC, JLFT, JKWF, DKYY, MPL. All authors have read and approved the manuscript. FUNDING INFORMATION This study received no external funding. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. ETHICS STATEMENT The study has been approved by the Research Ethics Committee (Kowloon Central/Kowloon East) of the Hospital Authority (Ref: KC/KE‐23‐0195/ER‐4). PATIENT CONSENT STATEMENT The Research Ethics Committee has waived the requirement for obtaining consent due to the study's retrospective nature. Supporting information Table S1. Definitions of conditions. Figure S1. Flowchart depicting inclusion and exclusion of PWH studied. Contributor Information Tommy Hing‐cheung Tang, Email: thc061@gmail.com. Ruby Tsz‐shan Kwong, Email: kts406@ha.org.hk. Man‐po Lee, Email: leemp@ha.org.hk. DATA AVAILABILITY STATEMENT The article includes original contributions from the study. For further information, please contact the corresponding authors. REFERENCES Associated Data Supplementary Materials Table S1. Definitions of conditions. Figure S1. Flowchart depicting inclusion and exclusion of PWH studied. Data Availability Statement The article includes original contributions from the study. For further information, please contact the corresponding authors.